Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 1
1968 1
1969 1
1974 2
1976 1
1977 1
1990 1
1997 2
1998 1
1999 1
2010 1
2012 3
2013 3
2015 4
2016 3
2018 3
2019 1
2020 4
2021 4
2022 5
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.
Follmann D, O'Brien MP, Fintzi J, Fay MP, Montefiori D, Mateja A, Herman GA, Hooper AT, Turner KC, Chan KC, Forleo-Neto E, Isa F, Baden LR, El Sahly HM, Janes H, Doria-Rose N, Miller J, Zhou H, Dang W, Benkeser D, Fong Y, Gilbert PB, Marovich M, Cohen MS. Follmann D, et al. Among authors: isa f. Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w. Nat Commun. 2023. PMID: 37330602 Free PMC article. Clinical Trial.
Patient reported outcome measures in rare diseases: a narrative review.
Slade A, Isa F, Kyte D, Pankhurst T, Kerecuk L, Ferguson J, Lipkin G, Calvert M. Slade A, et al. Among authors: isa f. Orphanet J Rare Dis. 2018 Apr 23;13(1):61. doi: 10.1186/s13023-018-0810-x. Orphanet J Rare Dis. 2018. PMID: 29688860 Free PMC article. Review.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. Among authors: isa f. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. Among authors: isa f. N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34347950 Free PMC article. Clinical Trial.
Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention.
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM. O'Brien MP, et al. Among authors: isa f. medRxiv [Preprint]. 2021 Jun 17:2021.06.14.21258567. doi: 10.1101/2021.06.14.21258567. medRxiv. 2021. PMID: 34159344 Free PMC article. Updated. Preprint.
iRAPs curb antisense transcription in E. coli.
Magán A, Amman F, El-Isa F, Hartl N, Shamovsky I, Nudler E, Schroeder R, Sedlyarova N. Magán A, et al. Among authors: el isa f. Nucleic Acids Res. 2019 Nov 18;47(20):10894-10905. doi: 10.1093/nar/gkz791. Nucleic Acids Res. 2019. PMID: 31535128 Free PMC article.
Prognostic evaluation of quick sequential organ failure assessment score in ICU patients with sepsis across different income settings.
Li A, Ling L, Qin H, Arabi YM, Myatra SN, Egi M, Kim JH, Nor MBM, Son DN, Fang WF, Wahyuprajitno B, Hashmi M, Faruq MO, Patjanasoontorn B, Al Bahrani MJ, Shrestha BR, Shrestha U, Nafees KMK, Sann KK, Palo JEM, Mendsaikhan N, Konkayev A, Detleuxay K, Chan YH, Du B, Divatia JV, Koh Y, Phua J; MOSAICS II Study Group; Asian Critical Care Clinical Trials Group. Li A, et al. Crit Care. 2024 Jan 23;28(1):30. doi: 10.1186/s13054-024-04804-7. Crit Care. 2024. PMID: 38263076 Free PMC article.
Etiologic and Anti-microbial Susceptibility Profiles of Bacterial Urinary Tract Infection and Bacterial Enteritis among Children at a Private Multi-Specialty Healthcare Facility in Abuja, Nigeria: A 5-Year Separate and Comparative Review.
Adeleye QA, Ndubuisi EC, Isa FA. Adeleye QA, et al. Among authors: isa fa. Niger J Clin Pract. 2024 Jan 1;27(1):35-46. doi: 10.4103/njcp.njcp_299_23. Epub 2024 Feb 5. Niger J Clin Pract. 2024. PMID: 38317033 Free article. Review.
49 results